“Development of a gut model system for the identification of anti-inflammatory probiotics”, Thomas Duboys. (07/07/2021) Biomillenia is proud to announce that our PhD student, Thomas Duboys, has successfully defended his thesis entitled “Development of a gut model system for the identification of anti-inflammatory probiotics” and as a result has obtained the title of Doctor of PSL University! This project was …
R&D Collaboration with Amyris
Paris/France—January 8, 2021: Biomillenia and Amyris, Inc., a leading synthetic biotechnology company in the development and production of sustainable ingredients for the Health & Wellness, Clean Beauty, and Flavors & Fragrances markets, announced today the signing of a R&D collaboration agreement aiming to evaluate Biomillenia’s microfluidics-based culture platform for phenotypic screening of Amyris’s engineered production strains. Biomillenia will contribute its …
New Biomillenia White Paper: Rethinking Culture-based Microbiology – Deep Insights into any Microbiota
• Do you need a microorganism cell bank for your natural samples that is as diverse as possible, and even includes rare species and previously uncultured species? • Do you need microorganism cell banks from small sample volumes, restricted samples (e.g., patient biopsies) or highly dilute samples? • Would you like to add sample-specific growth stimulators such as tissue fluids …
Biomillenia Launches Microbiome Culture Collection Service
Ability to identify novel bacterial strains based on functional traits at speeds and volumes never previously seen Partners will be able to create and build tailored, proprietary culture collection with previously unknown microbes Applications across industries – consumer health, food, animal health and agriculture Paris, France, 1st February, 2019 – Biomillenia, a company focused on restoring a robust and resilient …
Biomillenia Leverages QIAGEN Bioinformatics in Microbiome-on-a-Chip Discovery of Unculturable Microbes
Collaboration data presented at 3rd Annual European Microbiome Congress Microbiome-on-a-chip technology capable of culturing, screening and isolating bacteria in single step while demonstrating targeted benefits QIAGEN’s Microbial Genomics Pro Suite enables analysis of microbial sequences and microbiomes Paris, France, and London, UK, November 28, 2017—Biomillenia, the developer of Smart Microbes™, announced today a collaboration with QIAGEN N.V. (NASDAQ: QGEN, Frankfurt …
JOHNSON & JOHNSON INNOVATION awards prize to BIOMILLENIA
Paris, France, December 1st, 2016—BIOMILLENIA was selected as winner of the “Pitch Your Microbes” competition by the jury members at the European Microbiome Congress. The prize gives BIOMILLENIA access to the Johnson & Johnson Innovation JLINX facility. “This special recognition is a great support from the experts in the field valuing BIOMILLENIA’s unique capabilities for the discovery and development of non-GMO microbial …
BIOMILLENIA collaborates with MERCK on BIOevolution project
Paris, France, October 4, 2016—BIOMILLENIA announces its collaboration with the life science business of Merck on the development of an improved enzyme used in vaccine production processes. Following a successful technology evaluation project employing BIOMILLENIA’s proprietary droplet-based microfluidic cell culture and screening technology platform, BIOMILLENIA and Merck will collaborate on the development of a market-leading enzyme in Merck’s portfolio of …
BIOMILLENIA announces new scientific advisory board
Paris, France, August 15, 2016—BIOMILLENIA, an innovator in microbe strain development for the manufacturing of strains, natural ingredients and enzymes is delighted to announce the formation of its new scientific advisory board. The world-class team, consisting of leading experts from Europe and the U.S. who have made significant contributions in biotechnology, biological engineering, enzyme technology and microfluidics, will be chaired …
French President Mr. Hollande visits BIOMILLENIA at its new offices
Paris, France, March 14, 2016—French President Mr. Hollande visited today BIOMILLENIA at its new laboratories and office during the inauguration of the Pierre-Gilles de Gennes Institute in Paris. Scientific founder Andrew Griffiths (right on picture) explained to Mr. Hollande the BIOMILLENIA ultrahigh-throughput microfluidics platform for developing tailor-made enzymes and production strains. This novel disruptive technology platform allows the culturing and …
BIOMILLENIA moves to new offices
Paris, France, February 23rd, 2016 BIOMILLENIA will move its laboratories and office to the newly built business incubator at the Pierre-Gilles de Gennes Institute in Paris, France. Since starting operations in 2015, BIOMILLENIA entered into several agreements with leading companies in the US and Europe for developing improved versions of enzymes and production strains. The relocation of BIOMILLENIA to the IPGG …